| NCT ID | Title | Intervention(s) | Molecular eligibility | Population/age | Phase | Status | Sponsor | Key notes |
|---|---|---|---|---|---|---|---|---|
| NCT01524926 | CREATE: Cross-tumoral Phase 2 With Crizotinib | Crizotinib (PF-02341066) | Cross-tumoral enrollment including locally advanced/metastatic IMT; proven ALK and/or MET alteration **not mandatory** for registration | Children and adults; minimum age 1 year | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer (EORTC) | Included a predefined IMT cohort; dosing differed for patients aged ≥15 years vs younger children; foundational basket trial for crizotinib in IMT (pqac-00000017, pqac-00000022) |
| NCT03874273 | Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors | Crizotinib (Xalkori) 280 mg/m² twice daily, up to 24 months | Requires clear expression of rearranged **ALK/ROS1** genes | Pediatric only; age 0–18 years | Phase 2/3 | Unknown overall status; last known status recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology / Dmitry Rogachev National Research Center (Moscow) | Official title specifies recurrent, progressive, unresectable IMT; primary outcome ORR, with relapse-free survival and overall survival secondary endpoints (pqac-00000018) |
| NCT04094610 | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Repotrectinib (TPX-0005), oral | Requires qualifying **ALK, ROS1, or NTRK1-3** alterations; IMT listed among relevant conditions/keywords | Pediatric and young adult subjects; cohorts include pediatric and 12–25-year-old groups | Phase 1/2 | Recruiting | Turning Point Therapeutics, Inc. | Molecularly driven trial relevant to fusion-positive IMT; Phase 1 focuses on safety/RP2D, Phase 2 on anti-tumor activity in alteration-defined cohorts (pqac-00000019, pqac-00000023) |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors | Brigatinib monotherapy, oral | **ALK-positive** disease; includes dedicated ALK+ IMT expansion cohort | Pediatric and young adult patients; 1 to <26 years (phase 1 limited to ≤18 years) | Phase 1/2 | Recruiting | Princess Máxima Center for Pediatric Oncology (collaborator: Takeda) | Rolling-6 dose escalation followed by tumor-specific expansion; Cohort B1 is ALK+ IMT (planned n=12); objectives include RP2D, PK/safety, and ORR by RECIST 1.1 in IMT (pqac-00000020) |
| NCT03085186 | Treatment With Crizotinib Single Patient Expanded Access IND 134375 | Crizotinib | Pediatric IMT case; molecular criterion not stated in the available record excerpt | Single pediatric patient; 2-year-old male | Expanded access (not phase-assigned) | No longer available | Jean M. Tersak, M.D. / University of Pittsburgh (collaborator: Pfizer) | Single-patient expanded-access treatment intended to shrink lesion before safer surgical resection; directly relevant as real-world pediatric IMT use of crizotinib (pqac-00000021) |


*Table: This table summarizes ClinicalTrials.gov studies and expanded-access records relevant to inflammatory myofibroblastic tumor, including targeted agents, molecular entry criteria, age ranges, phases, and recruitment status. It is useful for quickly identifying current and completed precision-oncology options for ALK/ROS1/NTRK-altered IMT.*